Last 606.85 INR
Change Today +9.30 / 1.56%
Volume 295.8K
PIEL On Other Exchanges
Natl India
As of 5:39 AM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

piramal enterprises ltd (PIEL) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/30/13 - 649.40
52 Week Low
06/21/13 - 470.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

piramal enterprises ltd (PIEL) Related Businessweek News

No Related Businessweek News Found

piramal enterprises ltd (PIEL) Details

Piramal Enterprises Limited primarily manufactures and sells own and traded bulk drugs and formulations in India and internationally. It operates through three segments: Pharmaceuticals Businesses, Financial Services Businesses, and Information Management Business. The company provides custom manufacturing services across the entire drug lifecycle ranging from development and commercial manufacturing to off-patent supplies of active pharmaceutical ingredients and formulations. It also manufactures and sells inhalation anesthetics, intravenous anesthetics, regional anesthetics, muscle relaxants, and plasma volume expanders; and consumer products comprising vitamins and nutrition, analgesics, dermatological, antacids, and cough and cold products under various brands, such as Saridon, Lacto Calamine, i-Pill, Supractiv, etc. In addition, it discovers drugs primarily in the areas of oncology, inflammation, diabetes, and anti-infectives; offers biochemistry and hemaology analyzers; and provides bio-orthopedics research services. Further, the company offers BST-CarGel, a bio-scaffold for cartilage regeneration; and CALADRYL, an anti-pruritic solution for dermatosis application for minor skin irritations and itching. Additionally, it is developing Florbetaben, a specialized molecule used in positron emission tomography imaging that completed its Phase III clinical trials to detect beta-Amyloid plaque deposition in the brain; offers Web-enabled research and predictive analytics through proprietary databases and consulting services to the healthcare industry; and is involved in NBFC operations and real estate fund management business. The company was formerly known as Piramal Healthcare Limited and changed its name to Piramal Enterprises Limited in July 2012. Piramal Enterprises Limited is based in Mumbai, India.

4,347 Employees
Last Reported Date: 07/1/13

piramal enterprises ltd (PIEL) Top Compensated Officers

Chairman, Member of Nomination & Remuneration...
Total Annual Compensation: 57.3M
Chief Operating Officer, Executive Director a...
Total Annual Compensation: 31.9M
Vice Chairperson and Director of Strategic Al...
Total Annual Compensation: 27.5M
General Manager of Strategic Marketing, Execu...
Total Annual Compensation: 19.4M
Compensation as of Fiscal Year 2013.

piramal enterprises ltd (PIEL) Key Developments

Piramal Mulls Acquisitions

Piramal Enterprises Limited (BSE:500302) is seeking acquisition opportunities. Piramal Group plans to invest in three sectors where it has a presence-financial services, information management and healthcare. Ajay Piramal, Chairman of Piramal Enterprises, said “Financial services and information management are also sunrise sectors besides pharmaceuticals. And we are present in all three sectors.”

Piramal Enterprises Limited and Merisant India Private limited Enter into Sales & Distribution Partnership for Equal(R) in India

Piramal Enterprises Limited has partnered Merisant India Private limited for a sales & distribution partnership in India for its artificial table-top sweetener, Equal(R). Equal(R) is one of the artificial sweetener brands. The deal enables Merisant to tap into Piramal Enterprises strong distribution network in India, and allows the Consumer Product Division to expand its offerings in the self-care segment. Piramal Enterprises Consumer Products Division will distribute Equal(R) across chemists and general stores in India. This gives access to 231,000 retail outlets including 100% of pharmacy and cosmetic outlets in these cities. The division has a capability of ensuring the availability of any new product in stores within 21 days of its launch.

Piramal Enterprises Seeks To Sell Diagnostic Solution Business

Piramal Enterprises Limited (BSE:500302) plans to divest its diagnostics solution unit. Potential buyers that have shown interest in acquiring the diagnostics unit include the laboratory diagnostics arm of Siemens Healthcare and Abbott Diagnostics, said three persons familiar with the development who spoke on condition of anonymity. At least two "strategic players have shown interest in the asset, which is on the on the block now," said one of the three persons. Abbott India Ltd, which has an active presence in the diagnostic solutions and the reagents business in the local market, has been seeking to expand its market reach and product portfolio. Piramal Enterprises is moving to an industry-centric business model in which all its existing ventures are concentrated in two main areas of interest-healthcare and financial services. According to the second person, talks on the sale of the unit are at a preliminary stage now. "But it may be closed soon as it is purely strategic in nature, although a high valuation expected by Piramals could pose a hurdle in the current market situation."


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PIEL:IN 606.85 INR +9.30

PIEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocon Ltd 455.00 INR -2.20
Divi's Laboratories Ltd 1,325 INR +0.45
Jubilant Life Sciences Ltd 169.65 INR -1.35
Sanofi India Ltd 2,960 INR +56.40
Torrent Pharmaceuticals Ltd 555.60 INR +1.90
View Industry Companies

Industry Analysis


Industry Average

Valuation PIEL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.2x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.2x

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PIRAMAL ENTERPRISES LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at